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abSTracT
The aim of this study was to determine whether storage 
time had a significant effect on the platelet concentration of 
platelet-rich fibrin (PRF). Three blood samples were drawn 
from each participant into a sterile blood sampling tube. 
Two of the blood samples were centrifuged to form PRF. 
The third non-centrifuged sample was used to measure 
the baseline blood platelet concentration. After PRF had 
formed, it was removed from the respective test tubes at 
different time intervals i.e. immediately after centrifugation 
(Group A) and after 60 min of storage time in the blood 
collecting tube (Group B). The residual blood from each 
group was tested for platelet concentration and compared 
with the baseline reading (as an indirect measure of the 
platelet concentrate of PRF). The PRF produced in Group 
A (PRF A) had a mean platelet concentration of 274 
±57.8×109/L, whereas the PRF of Group B (PRF B) was 
278 ± 58.2×109/L. A statistically significant difference was 
seen between the groups (p < 0.001). 
conclusions: Storage time has a significant effect on the 
platelet concentration of PRF. Further research is required to 
determine whether this has any clinical relevance.
InTroducTIon
Wound healing is a complex process characterised 
by the repair and reconstitution of lost or damaged 
tissue. Identification of the pathological and biochemical 
mechanisms that regulate tissue repair and homeostasis has 
long been regarded as central to their therapeutic exploitation 
in the clinical setting. By the mid-1990s, several methods 
were proposed to enhance wound healing, including the 
administration of high concentrations of human platelets to 
affected areas.1-6 It was assumed that platelets optimised 
wound healing by promoting the secretion of growth factors 
(GFs) necessary for tissue repair.7-9 The most common 
platelet concentrate used in these procedures is platelet-rich-
plasma (PRP) and by the early part of the 21st century, its 
use in various surgical procedures was commonplace.1,4,10,11 
However, the preparation of PRP often requires the use 
of specialised equipment, chemicals and animal-derived 
additives. This increases the risk for complications secondary 
to allergic reactions to certain animal-derived additives.12-14 
As a result, researchers have sought more efficient and safer 
methods of concentrating platelets for surgical use.1 This 
led to the production of platelet-rich-fibrin (PRF), a platelet 
concentrate that neither contained additives nor required 
the use of specialised equipment during its preparation. First 
introduced by Choukroun et al (2001), PRF has been studied 
extensively and is now regarded as a biological scaffold 
different to PRP.15 However, even though the use of PRF is 
gaining widespread clinical acceptance, several questions 
regarding its biological stability remain unanswered.16,17 The 
aim of this this study was to analyse the effect of storage time 
on the platelet concentration of this unique biomaterial.
maTerIalS and meTHodS 
The study was conducted under the principles outlined 
by the “World Medical Association Declaration of Helsinki, 
Ethical Principles for Medical Research Involving Human 
Subjects” of 2008. Ethical approval was obtained from the 
Ethics Committee of the University of the Western Cape 
(Registration number 11/4/29). All participants were fully 
informed of the research protocol and were required to sign 
a declaration of informed consent before being allowed to 
participate in this cohort analytical study. A total of 30 healthy 
participants (16 females and 14 males) were enrolled into 
the study. Participants were drawn from the current patient 
pool as well as staff members based at the Dental Faculty, 
University of the Western Cape. All participants had three 
separate blood samples collected by venipuncture. Two 
of the samples were acquired using tubes containing clot 
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activators, i.e., Vacuette® 10ml serum tubes with Z Serum 
Clot Activator (Greiner BioOne International AG, Germany), 
whereas the remaining blood sample was drawn into a 10ml 
BD Vacutainer® tube that contained dipotassium-EDTA, an 
anticoagulant (BD Diagnostics, New Jersey USA).
 
All the blood samples collected in the anticoagulant-
containing tubes were used to measure baseline platelet 
concentrations, whereas the remaining blood samples 
(collected in the Clot Activator containing tubes) were used 
to prepare PRF by centrifugation (400g for 12 minutes) 
in a standard benchtop centrifuge (PLC-03, Hicare 
International, Taiwan) (Figure 1). Therefore, from each study 
participant, two samples of PRF were obtained (Figure 2). 
The two PRF samples were then randomly allocated into 
either Group A or Group B, using a simple coin toss. 
For Group A, the PRF was removed from the tube 
immediately after preparation (0min), whereas for Group 
B, the PRF remained in the tube and was only removed 
after 60 minutes. The PRF produced from each group 
was designated PRF A and PRF B respectively.  Because 
a direct measurement of platelet concentration of PRF 
is not yet possible, we calculated the PRF concentration 
for each group indirectly, by determining the numerical 
difference between the residual platelet concentration (of 
the remaining serum after removal of PRF) and the baseline 
platelet concentration for each specific study participant. In 
this study, platelet concentration analysis was carried out 
using an electronic automated cell counter (Advia 2120, 
Siemens AG, Erglangen, Germany).
Data was collected and entered into a spreadsheet 
(Microsoft Office 2010 Excel, Microsoft Corporation, 
Washington). The results were compared and analysed 
statistically using SPSS® Version 13 for Windows.  
reSulTS and dIScuSSIon
A total of 30 participants (16 females and 14 males) were 
entered into the study. The mean age of the participants 
was 41.7 years, with male sub-
jects being slightly younger than 
their female counterparts (41.3 
years for males vs 42 years for 
females). The youngest partici-
pant was 24 years old and the 
oldest, 58 years old.
Platelet concentrations obtained 
from analysis of all 30 participants 
were within the normal laboratory 
reference range of 170-400×109L 
of circulating blood. None of the 
participants displayed any sig-
nificant haematological disease. 
The mean blood platelet concen-
tration was 282.8×109/L (Table 1). 
There was no significant differ-
ence between the genders. 
After removal of formed PRF from 
Group A, the residual serum yield-
ed minimal concentrations of platelets. The mean concentra-
tion of remaining platelets was 7.9×109/L (Table 2). For Group 
B, serum platelet concentrations were also minimal after re-
moval of the prepared PRF with the mean concentration of 
the platelets being 4.0×109/L (Table 2). 
The residual mean platelet concentration of Group A was 
higher than that determined for Group B with the mean 
difference in platelet concentrates between the two 
groups being 3.90 × 109/L. Using a non-parametric Signed 
Rank Test, the statistical significance of the differences in 
platelet concentrates between the Groups A and B was 
analysed. The difference between the two groups was 
statistically significant (p < 0.001).
The platelet concentration of PRF for both groups was cal-
culated using the difference between baseline and residual 
platelet concentrations (Table 3). A paired t-test showed a 
statistically significant difference between the two groups 
(p < 0.001) (Table 4).
figure 1: Benchtop centrifuge figure 2: Prepared PRF





Table 2: Mean baseline platelet concentration of residual blood 
in cells x  109/l of blood
mean n Std. deviation Std. error mean
Group a 7.9 30 3.03 0.55
Group b 4 30 1.93 0.35
Table 3: Mean calculated PRF platelet concentration in cells x 
109/l of blood
mean Std. deviation minimum maximum
Prf a 274.9 57.8 169 387
Prf b 278.8 58.2 171 390
Table 4: Statistical analysis of PRF A and PRF B
mean Std. Deviation Std. Error Mean 95% Confidence Interval of the Difference t df Significance (2-tailed)
Lower Upper
-3.9 3.133 0.572 -5.07 -2.73 -6.818 29 0.001
* Paired t-test performed, P value is significant
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dIScuSSIon
The purpose of this study was to determine whether stor-
age time had any significant effect on the platelet concen-
tration of PRF. Because the structural properties of the 
PRF clot does not allow for a direct measurement of its 
platelet concentration, we used the residual platelet values 
left in the blood tube after removal of the PRF clot as an 
indirect measurement of the platelet concentration in the 
PRF clot. This is in accordance with a previously published 
method.18 Higher residual values indicate that less platelets 
were contained in the removed clot whereas lower residual 
values would indicate that more platelets were transferred 
to the clot. The results from this study indicate that there is 
a significant difference in the mean platelet concentration of 
PRF when stored for 0 and 60 minutes.
From the platelet counts obtained in both test groups it 
was clear that a significant proportion of platelets had 
been removed from the blood after extraction of the PRF 
clots. In fact, when differences between the test groups 
and the baseline blood sample were compared, it was evi-
dent that 97%-98% of the platelets were concentrated in 
the PRF clot (Table 3). This observation is similar to results 
published for previous studies (97%).19 The natural proc-
ess of fibrin and clot formation that occurs in the blood 
collecting tubes results in the entrapment of the majority 
of the available platelets in a fibrin matrix. This acts as a 
reservoir for a concentration of growth factors (GFs) re-
quired in the initial stages of wound healing.20
Although the physiology of PRF has been studied extensive-
ly, very few reports adequately document the ability of this 
platelet concentrate to be stored.21 Previous research has in-
dicated that storing PRF under certain conditions may affect 
its ability to clinically yield positive results.22 In fact, it is not 
recommended to store the platelet concentrate in its blood 
collecting tube since it is assumed that it may disintegrate 
into an unusable form after about 15 minutes of storage.22 
Instead, several authors propose storing the biomaterial in 
a metal dish or a proprietary designed storage box.17 Data 
regarding the maximal storage time and ideal storage tem-
perature of PRF are, however, largely lacking. 
In this study, we used standard blood collecting tubes 
with clot activators to store PRF for at least 60 minutes 
at room temperature. This particular duration of time 
was chosen based on the average time of typical peri-
odontal surgical procedures at the Faculty of Dentistry, 
University of the Western Cape. The results of the study 
indicate that by using the presented protocol for platelet 
concentrate preparation, it was possible to concentrate 
more than 97% of the available blood platelets into a read-
ily usable form. This study also showed that by using the 
blood collecting tubes as a storage medium, there was 
no detrimental effect on the platelet concentration of PRF. 
Indeed, storing the concentrate for 60 minutes resulted in 
a form of PRF that had significantly higher concentrations 
of platelets compared with non-stored PRF. The reason 
for this phenomenon is unclear, but may be related to the 
“clot activators” that line these tubes. Clot activators are 
often silica based and are used in plastic tubes to mimic 
the clotting effect of glass based blood tubes.22 As a re-
sult, a longer contact time between blood and these ac-
tivators may enhance fibrin activation and clot formation, 
with subsequent platelet entrapment.18 
Another reason for the variation in platelet concentration 
seen in this study may be that the recommended centri-
fuge time is too short to allow for complete clot forma-
tion to occur. Therefore, allowing the PRF clot to remain 
in the tube for a period longer than the recommended 
time, may result in a more complete physiological reac-
tion taking place.
The ability of PRF to sustain its platelet concentrate over 
the tested time may have significant clinical implica-
tions.8,9,22-24 Rather than having to draw blood during the 
surgical procedure, it allows for blood to be drawn before 
the start of the procedure, thereby improving patient com-
fort and saving operator time. The option to store the PRF 
in the same tubes in which it was formed negates expo-
sure to other environmental factors that may contaminate 
the sample. It is also cost-effective, since no specialised 
equipment or storage facilities are required. This may be 
significant in resource-poor settings. 
PRF has been recognised as a biomaterial that includes 
living cells.18,19 In order to sustain cell viability over time, an 
isotonic solution is required for storage. The blood collect-
ing tubes, although not designed to store blood, act as 
containers for the PRF and the remaining formed elements 
and serum. Consequently, when PRF is stored in the blood 
that it was derived from, the remaining serum acts as a 
natural isotonic solution that sustains cell survival.
The release of growth factors is a significant property of 
blood platelets.24 Previous studies indicate that several of 
these factors play an essential role in osteogenesis and 
periodontal regeneration.20,25 When PRF is used, the re-
lease of these growth factors appears to be constant, 
and over a longer period of time when compared with 
that seen with PRP.23 In a direct comparison between the 
two, PRP was shown to have an initial larger release of 
growth factors after activation. However, these high con-
centrations were not stable and decreased over time. On 
the other hand, PRF releases less growth factors initially, 
but sustains this release for a longer duration.23 A number 
of authors speculate that this may be due to the fibrin 
clot that forms a network and acts as a reservoir for the 
trapped platelets.18,19,26 In the present study, it was shown 
that the platelet concentration of PRF improved over a pe-
riod of 60 minutes of storage. We assume that this may 
be due to prolonged fibrin clot maturation. It is therefore 
reasonable to speculate that if PRF is stored until optimal 
fibrin formation is achieved, then higher concentrations 
of growth factors may be available from the PRF during 
wound healing. Whether this has any clinical significance 
requires further investigation.
Temperature may affect the storage potential of PRF and 
it has been suggested that storing it in near-freezing tem-
peratures is not advisable. In this study, all the samples 
were stored at room temperature. It was clear that storage 
under these conditions had no detrimental effect on the 
platelet concentration of the PRF clot.
Although the present study showed statistically significant 
differences between the two groups tested, some limita-
tions were also evident. These include the limited number 
of study participants as well as the inability to directly meas-
ure the platelet concentration of PRF. Other factors include 
the small difference between the platelet concentrations of 
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the groups tested. Although statistically significant, a mean 
difference of only 3.9 × 109 cells/L may not be clinically rel-
evant and therefore further research is warranted to deter-
mine the clinical significance of these findings.
concluSIonS
The viability of storing PRF in its own blood collecting 
tubes has not yet been reported. This study showed that 
by using the above method of platelet preparation, it is 
possible to concentrate more than 97% of the available 
platelets into a PRF clot. The study also indicated that, un-
like in previous reports, clot disintegration does not take 
place after 15 minutes of storage, but rather remains sta-
ble over a period of at least 60 minutes and may in fact 
increase in platelet concentration during that time. Further 
investigations are warranted to determine whether this 
has any clinical implications.
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